<DOC>
	<DOCNO>NCT03007004</DOCNO>
	<brief_summary>Efficacy safety local infusion botulinum toxin type B patient systemic sclerosis ( SSc ) digital ulcer evaluate randomized , double-blind study .</brief_summary>
	<brief_title>Effect Safety Local Injection Botulinum Toxin Type B Against Digital Ulcer Systemic Sclerosis</brief_title>
	<detailed_description />
	<mesh_term>Sclerosis</mesh_term>
	<mesh_term>Ulcer</mesh_term>
	<mesh_term>Scleroderma , Systemic</mesh_term>
	<mesh_term>Scleroderma , Diffuse</mesh_term>
	<mesh_term>Skin Ulcer</mesh_term>
	<mesh_term>Botulinum Toxins , Type A</mesh_term>
	<mesh_term>incobotulinumtoxinA</mesh_term>
	<mesh_term>abobotulinumtoxinA</mesh_term>
	<mesh_term>onabotulinumtoxinA</mesh_term>
	<mesh_term>Botulinum Toxins</mesh_term>
	<mesh_term>rimabotulinumtoxinB</mesh_term>
	<criteria>1 . Patients diagnose SSc diagnostic criterion ( Appendix 1 ) AmericanEuropean Rheumatology Association 2 . Patients Raynaud 's phenomenon consultation , inquiry , etc . judge Clinical responsibility ( share ) doctor 3 . Patients digital ulcer acquire consent The criterion digital ulcer follow . It peripheral ulcer proximal interphalangeal joint thumb interphalangeal joint ( include interphalangeal joint ) . The continuity coat epithelium lose depth visible eye . Incidentally , expose , case cover eschar necrotic tissue also include . If exposure clearly recognize ( crust cover necrotic tissue ) , investigational responsibility ( share ) doctor judge epidermis dermis miss . It paronychia、crack、digital pit scar . It attach projection calcification . Size : The maximum diameter ( major axis ) 0.5 cm . Bones , tendon joint expose . It accompany obvious infection finding . 4 . At time acquire consent Patients 18 year old 5 . Patients consent obtain write participation trial 1 . Patients Raynaud 's phenomenon due diseases SSc 2 . Patients systemic neuromuscular junction disorder ( myasthenia gravis , LambertEaton syndrome , amyotrophic lateral sclerosis etc . ) 3 . Patients advance respiratory dysfunction 4 . Patients history hypersensitivity component botulinum toxin type B ( botulinum toxin type B , human serum albumin , succinate buffer ) botulinum toxin 5 . Patients receive botulinum toxin formulation within 4 month study drug administration continue efficacy botulinum toxin time administration investigational drug even administer 4 month ago 6 . Patients receive endothelin receptor antagonist within 60 day study drug administration 7 . Patients receive following medication within 14 day prior study drug administration Argatroban hydrate injection Prostaglandin E1 Injection ( eg alprostadil injection )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2016</verification_date>
	<keyword>Systemic aclerosis</keyword>
	<keyword>digital ulcer</keyword>
	<keyword>botulinum toxin</keyword>
</DOC>